Ninety-three patients with surgically resected loco-regional metastases (24 initial stage IIIA/B and 69 former stage I/II patients) were enrolled into the follow-up programme, in 60 out of 93 stage III patients a relapse was documented (64.5%) within a median time of 7.8 months.
Only 4.8% of patients with first-stage illness experienced a relapse; direct evidence of the parasite was found in 27% of these case-patients.
Female patients ≥18 years of age with histologically confirmed HER2-positive invasive breast cancer (defined as HER2 positive score [>2.2] by fluorescence in situ hybridization or 3+ amplification by immunohistochemistry) who presented with de novo stage IV disease or had stage IV disease at a relapse after curative-intent surgery were enrolled in the study.
Other exclusion criteria included a personal history of ovarian cancer (any stage); breast cancer (stage IIB or higher); DCIS, Stage I or Stage IIA breast cancer with a relapse after primary treatment; or any other invasive cancer except non-melanoma skin cancer or cervical carcinoma in situ, unless relapse-free for 5 years prior to the time of enrollment.
This is consistent with the findings in a study by Dupont et al (2005) where 22% of patients having stage IB disease and 60% having stage IIA disease experienced a relapse.
Admittedly, the composition of our study cohort may lead to a bias, with cases enriched for high-grade and high-stage tumours, leading to a relapse rate of 46%, which is approximately 15 percentage points above the usual rates of consecutive RPE cohorts.
After staging a recovery it suffered a relapse when Ireland required an emergency rescue.
Given the lack of evidence on the risk of cancer relapse by stage, a complete remission seems to be a reasonable pre-requisite before the initialization of immunosuppressive treatment is considered.
Recurrence was defined as recurrence of primary NMIBC with a lower or the same pathological stage, and progression was defined as disease with a higher TNM stage upon relapse.
Therefore, GMA at an early stage following a clinical relapse is likely to induce remission of an active UC.
